Avoid common mistakes on your manuscript.
Dear Reader,
Welcome to the final issue of BioDrugs for 2020. I wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of our content.
The high quality of the content published in BioDrugs has been reflected in the most recent Impact Factor of 5.313. This places the journal in the first quartile of the Immunology, Oncology, and Pharmacology & Pharmacy categories. Furthermore, BioDrugs has published content in a timely manner, with an average time from submission to acceptance of 89 days.
In 2020, over 60 articles have been published. The most popular of these in terms of downloads from SpringerLink have been
-
The Therapeutic Potential of Nanobodies. https://doi.org/10.1007/s40259-019-00392-z
-
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies. https://doi.org/10.1007/s40259-020-00412-3
-
The Path Towards a Tailored Clinical Biosimilar Development. https://doi.org/10.1007/s40259-020-00422-1
-
Cell-Free Protein Synthesis: A Promising Option for Future Drug Development. https://doi.org/10.1007/s40259-020-00417-y
-
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! https://doi.org/10.1007/s40259-019-00395-w
-
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. https://doi.org/10.1007/s40259-020-00419-w
-
The Importance of Countering Biosimilar Disparagement and Misinformation. https://doi.org/10.1007/s40259-020-00433-y
-
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. https://doi.org/10.1007/s40259-020-00430-1
-
Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology. https://doi.org/10.1007/s40259-020-00407-0
-
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). https://doi.org/10.1007/s40259-019-00398-7
This year has presented many challenges and I would like to take this opportunity to thank all who have contributed to ensuring the journal has thrived despite the extraordinary circumstances that the science community, and the world in general, has faced.
I would like to start by thanking the authors of the articles published in BioDrugs over the course of 2020. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.
The quality of published articles is also testament to the diligence of the peer reviewers, whose willingness to share their expertise ensures that the journal’s content is held to the highest standard. I would like to acknowledge the following individuals who acted as reviewers for BioDrugs in the last 12 months:
Hesham Abboud, USA
Mohammed I. Aladul, Iraq
Saja Alnahar, Jordan
Marina Aloi, Italy
Vito Annese, United Arab Emirates
Federico Arguelles-Arias, Spain
Stephen Attwood, UK
Yves Aubin, Canada
Vladimir Baklaushev, The Russian Federation
Michael Barry, Ireland
Dorthe Bartels, Denmark
Bridget Bax, UK
Andrea Becciolini, Italy
Alain Beck, France
Charles L. Bennett, USA
Shubha Bhat, USA
Lokesh Bhatt, India
Saveri Bhattacharya, USA
Elizabeth Buchbinder, USA
Ted M. Burns, USA
Kim Chan, Australia
Zhilei Chen, USA
Narendra Chirmule, USA
Carlo Chizzolini, Switzerland
Hannah Choe, USA
Catalin Codreanu, Romania
Hillel P. Cohen, USA
Jeffrey A. Cohen, USA
Romain Cohen, France
Tünde Csepany, Hungary
Fraser Cummings, UK
Paola M. Cutroneo, Italy
Michael R.R. da Silva, Brazil
Jonathan J. Darrow, USA
Satya Das, USA
Fernando de Mora, Spain
Carlo DeAngelis, Canada
Rossella Di Bidino, Italy
Dario Dilillo, Italy
Richard Dolinar, USA
Juan Dominguez-Robles, UK
Alexandros A. Drosos, Greece
Hans Ebbers, Switzerland
Mark S. Freedman, Canada
Nils E. Gilhus, Norway
Brian Godman, Sweden
Guro Goll, Norway
Elisabete Gonçalves, Portugal
Maria Greenwald, USA
Hildegard Greinix, Austria
Henning Gruell, Germany
Maria Guerra Veloz, Spain
Grace Hampson, UK
Lora Hamuro, USA
Graham F. Hatfull, USA
A. Barney Hawthorne, UK
William Hogan, USA
Kevin Hollevoet, Belgium
Li-feng Hsu, Taiwan, Republic of China
Michael Hurwitz, USA
Elisabeth Husar, Switzerland
Rohit Jain, USA
Robyn V. Jamieson, Australia
Molly M. Jeffery, USA
Bengt Jonsson, Sweden
Kristin Jorgensen, Norway
Carol Kirchhoff, USA
Ingo Kleiter, Germany
Roland E. Kontermann, Germany
Andrew J. Krentz, UK
Sherko Kümmel, Germany
Pekka Kurki, Finland
Christopher Lao, USA
Chris A. Liacouras, USA
Michael N. Liebman, USA
Jennifer Liu, USA
Ruth Lopert, USA
Ersilia Lucenteforte, Italy
Fabio Salvatore Macaluso, Italy
Marina A. Machado, Canada
Robert MacLaren, UK
Ivan Marquez-Rodas, Spain
Paul J. Martin, USA
Eva Martínez-Cáceres, Spain
Jennifer C. Massey, Australia
Emad Massoud, Canada
Anne Messer, USA
Jorge Mestre-Ferrandiz, Spain
Markus Mezger, Germany
Lotte Minnema, The Netherlands
Timothy A. Moseley, USA
Serge Muyldermans, Belgium
Vladimir R. Muzykantov, USA
Sumimasa Nagai, Japan
Jun-ichi Nishimura, Japan
Shin Nishio, Japan
Konstantinos Papamichael, USA
Nikolaos Papanas, Greece
Maria Kristina Parr, Germany
Atul Patel, India
Himanshu Patel, India
James R. Patrinely, USA
Christopher J. Patriquin, Canada
Regis Peffault deLatour, France
Franck Perez, France
Diana P. Pires, Portugal
Zhigang Qi, China
Joannes A.A. Reijers, The Netherlands
Wolfgang F. Richter, Switzerland
Timothy Rudd, UK
Piotr Rutkowski, Poland
Danay Saavedra, Cuba
Donald B. Sanders, USA
Andrea Sartore-Bianchi, Italy
Edoardo Savarino, Italy
Huub Schellekens, The Netherlands
Martin Schiestl, Austria
Anna Serrano-Mollar, Spain
Kichul Shin, Republic of Korea
Francesca Romana Spinelli, Italy
Sarah A. Stewart, UK
Ivana Stojanovic, Serbia
Vibeke Strand, USA
Antoinette Tan, USA
Deborah Lynn Toppmeyer, USA
Maria Trovato, Italy
Asterios S. Tsiftsoglou, Greece
Marco Tuccori, Italy
John Valentine, USA
Tsvetelina Velikova, Bulgaria
Pablo Villoslada, Spain
Arnold G. Vulto, The Netherlands
Jiang-Hui Wang, Australia
Chao Wang, USA
Christopher J. Webster, USA
Jeffry Weers, USA
James C-C. Wei, Taiwan, Republic of China
Martina Weise, Germany
Wendy W. Weston, USA
Astrid Wiens, Brazil
Andrew Wilber, USA
Elena Wolff-Holz, Germany
Sarah Yim, USA
Dae Hyun Yoo, Republic of Korea
Xiaofeng Zeng, China
Libo Zhao, China
I am also very grateful to the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes.
Lothar Bergmann, Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany
George D. Demetri, Dana Farber Cancer Institute, Boston, MA, USA
Terence R. Flotte, University of Massachusetts Medical School, Worcester, MA, USA
Timothy M. Ganey, Vivex Biomedical, Atlanta, GA, USA
Arnold Ganser, Hannover Medical School, Hannover, Germany
Hans-Peter Gerber, 3T Biosciences, Palo Alto, CA, USA
Thijs J. Giezen, Foundation Pharmacy for Hospitals in Haarlem, Haarlem, The Netherlands
Bernd Groner, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany
Francois Guilhot, Université de Poitiers, Poitiers, France
William H. Hildebrand, University of Oklahoma, Oklahoma City, OK, USA
Phillippe Moingeon, Stallergenes, Paris, France
Dafne Müller, Universitat Stuttgart, Stuttgart, Germany
Won Park, Inha University Medical School, Incheon, Republic of Korea
Cesar Picado, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
Thomas Schirrmann, YUMAB GmbH, Braunschweig, Germany
Susan Sharfstein, SUNY Polytechnic Institute, Albany, NY, USA
Cy A. Stein, City of Hope Medical Center, Duarte, CA, USA
Raymond C. Stevens, University of Southern California, Los Angeles, CA, USA
William R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA
Bruce A. Sullenger, Duke University Medical Center, Durham, NC, USA
Jonathan Terrett, CRISPR Therapeutics, Inc., Cambridge, MA, USA
Gianluca Trifirò, University of Messina, Sicily, Italy
Piotr Trzonkowski, Medical University of Gdansk, Gdansk, Poland
Jos W. van der Meer, Radboud University Medical Center, Nijmegen, The Netherlands
Gillian Woollett, Avalere Health, Washington, DC, USA
The COVID-19 pandemic has reinforced the importance of rapid and wide dissemination of high-quality information. Springer Nature is supporting the global response to COVID-19 by making all relevant content immediately and freely available, including the following articles in BioDrugs:
-
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. https://doi.org/10.1007/s40259-020-00430-1
-
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour? https://doi.org/10.1007/s40259-020-00448-5
In 2021, BioDrugs will continue to provide you with high interest, clinically relevant content in the field of biotechnology-based pharmaceuticals for the treatment of human disease. I thank you for your continued support.
With best wishes,
Kathy Fraser, Editor
Rights and permissions
About this article
Cite this article
Acknowledgement to Referees. BioDrugs 34, 701–704 (2020). https://doi.org/10.1007/s40259-020-00455-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-020-00455-6